Floatz logo

Pembrolizumab

Skin Cancer

Institute of Oncology Ljubljanamonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Skin Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Dana-Farber Cancer Institute
Phase 4BBB
Cyclophosphamide
Institute of Oncology Ljubljana
Phase 2BB
Rapamycin
Dana-Farber Cancer Institute
Phase 4BB
Nivolumab
7 Hills Pharma, LLC
Phase 3BB
Fludarabine
H. Lee Moffitt Cancer Center and Research Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →